UnitedHealth Group is under investigation by the Justice Department **over its Medicare billing prac ...

Hims & Hers, one of the most popular telehealth services in the world, is in danger of losing one of its central revenue sources. The U.S. Food and Drug Administration (FDA) removed semaglutide ...

The ruling shows Novo Nordisk’s confidence that the supply of semaglutide will be stable for now.

The telehealth company has been selling a copycat version of a popular obesity drug during the recent shortage.

The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...

Semaglutide is a glucagon-like peptide-1 (GLP-1) that helps regulate blood sugar levels. Because of outsized demand for ...

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 24% in the afternoon session after U.S. Food and Drug Administration (FDA) reported that the shortage of weight-loss drugs such as ...

Ozempic and Wegovy, the widely popular forms of semaglutide sold to treat diabetes and obesity, have officially been removed ...

Hims & Hers Health shares swooned after the Food & Drug Administration said the active ingredient in Ozempic and Wegovy is no longer in short supply. The company makes compounded versions of ...

Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...

The FDA has now resolved the shortages of Novo Nordisk and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

With the formation of the BJP government in Delhi, an action plan has been prepared to introduce key reforms in the healthcare sector, which includes digitisation of health services, setting up of ...